1,729,880 research outputs found
Indian Pharma Within Global Reach?
Get PDFThe Indian pharmaceutical industry is presently going through a phase of transition and potential consolidation, owing to India's new TRIPS-compliant intellectual property regime and other rules aimed at enhancing the industry's credibility nationally and internationally. Appropriate policy interventions can play a large role in cushioning the transition (and gradual consolidation) of the industry post-2005. Using firm level data collected in 2004-2005, this paper seeks to make two major contributions in this regard. The research findings show that the Indian pharmaceutical sector is a heterogeneous mix of firms with vast differences in innovative capabilities. Based on these differences, the groups can be categorized into specific "innovation modes" (the innovator, the niche operator and the manufacturer), each mode being a step closer towards the innovative pharmaceutical firm. Second, the paper highlights how the emerging strategies of firms in all three groups, although different, underpin the importance of systemic coordination in the pharmaceutical sector. The analysis links both these findings to policies pursued in the pharmaceutical sector over the past four decades and highlights the role of differential innovation policy in ensuring optimal sectoral performance.Pharmaceutical industry, Innovation policy, TRIPS, Intellectual Propery, IPR, Property rights, India
India's product patent protection regime: Less or more of "pills for the poor"?
Get PDFThe year 2005 marks the end of transition period for many developing countries with competent pharmaceutical sectors that competed in supplying generic versions of patented drugs to LDCs before, thereby inducing price competition and enhancing access to medicines. In a post-2005 scenario, the critical issue is whether LDCs without adequate manufacturing capabilities can make use of compulsory licensing expeditiously to induce price competition and secure lower prices. This paper uses empirical evidence collected during a firm-level survey of the Indian pharmaceutical sector to generate evidence on emerging strategies of firms. It shows that the vigour of compulsory licensing as a price-leveraging instrument post-2005 is incumbent mainly on its economic feasibility. It shows that Indian firms view the market potential (in terms of market size and profits involved in such supply, especially if they have to make specific technological investments to produce the drug) of the mechanism much more severely than before, and may be less inclined to engage in such production if their commercial expectations are grossly unmet. The analysis assesses implications of emerging strategies of firms in the Indian pharmaceutical sector for access to medicines both domestically and internationally, and highlights the challenges involved.product patents, Indian pharmaceuticals, generics, access
Annual Report on Indian Epigraphy for 1994-95
No full textM.D. Sampath, Annual Report on Indian Epigraphy for 1994-95 (New Delhi: Archaeological Survey of India, 2001
Supplemental Table 1: MMS specific CPT codes with descriptions
No full textMMS specific CPT codes with description
Validation of the name Persea himalayensis (Lauraceae)
No full textKumar, Venkatachalam Sampath, Gangopadhyay, Mohan (2013): Validation of the name Persea himalayensis (Lauraceae). Phytotaxa 92 (2): 59-60, DOI: 10.11646/phytotaxa.92.2.5, URL: http://dx.doi.org/10.11646/phytotaxa.92.2.
Effects of nanocrystalline calcium deficient hydroxyapatite incorporation in glass ionomer cements
No full textAbstract not availableSumit Goenka, Rajkamal Balu, T.S. Sampath Kuma
Annual Report on Indian Epigraphy for 1993-94
No full textKatti, M.N and M.D. Sampath, Annual Report on Indian Epigraphy for 1993-94 (New Delhi: Archaeological Survey of India, 1999
- …
